ATOSSA THERAPEUTICS, INC.

ATOS ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017 FY2016 FY2015 FY2014 FY2013 FY2012 FY2011 FY2010
Operating Activities
Net Income $-8.1M $-6.4M $-15.8M $-14.7M $-10.8M $-5.1M $-3.4M $-1.1M
Depreciation & Amortization $129.0K $303.5K $272.6K $480.3K $472.9K $130.6K $15.6K
Depreciation $26.0K $125.7K $73.1K $144.9K $83.0K $25.1K $3.9K
Amortization $103.0K
Stock-Based Compensation $840.1K $556.3K $1.4M $121.8K $140.1K
Net Cash from Operating Activities $-6.6M $-5.4M $-14.0M $-10.6M $-8.8M $-3.9M $-3.5M
Investing Activities
Capital Expenditures
Business Acquisitions
Net Cash from Investing Activities $-9.2K $-288.4K $-343.3K $-134.6K $-136.9K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $10.8M $4.7M $3.8M $5.5M
Net Change in Cash $4.2M $-687.9K $-4.8M $2.2M $4.6M $-185.6K $1.9M
Free Cash Flow
← Newer Page 2 of 2 Older →